Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US-2015359913-A1 · Dec 17, 2015 · US
PET probes of radiofluorinated carboximidamides for IDO-targeted imaging
US10183082B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183082-B2 |
| Application number | US-201515505214-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2015 |
| Priority date | Sep 9, 2014 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
18 F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-mino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18 F. The 18 F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.
First claim
Opening claim text (preview).
We claim: 1. An 18 F labeled IDO1 imaging construct, comprising a molecule having the following structure: 2. A method of performing positron emission tomography (PET), comprising injecting a solution comprising an 18 F labeled IDO1 imaging construct into a patient suspected of having cancer; and imaging the patient with PET, wherein the 18 F labeled IDO1 imaging construct comprises a molecule having the following structure: 3. The method according to claim 2 , wherein the cancer is breast cancer. 4. The method according to claim 2 , further comprising administering a treatment for the cancer to the patient before, during, or after injecting the solution. 5. The method according to claim 4 , wherein the treatment comprises administration of surgery, radiation, chemotherapy, immunotherapy, or a combination of two or more of the foregoing. 6. The method according to claim 4 , wherein the treatment comprises administering an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1) to the patient. 7. The method according to claim 4 , wherein the treatment comprises administering a combination of an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1) and a different cancer treatment simultaneously or consecutively. 8. The method according to claim 4 , wherein the patient is human. 9. A method for treating cancer in a patient, comprising administering a treatment for the cancer to the patient; and injecting a solution comprising an 18 F labeled IDO1 imaging construct into the patient, wherein the 18 F labeled IDO1 imaging construct comprises a molecule having the following structure:
Assignees
Inventors
Classifications
- A61K51/0453Primary
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles · CPC title
having two nitrogen atoms and only one oxygen atom · CPC title
Preparations for testing in vivo · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10183082B2 cover?
- 18 F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-mino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18 F. The 18 F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.
- Who is the assignee on this patent?
- H Lee Moffitt Cancer Ct & Res
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0453. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).